The role of postoperative radiation therapy in carcinoma ex pleomorphic adenoma of the parotid gland

2007 ◽  
Vol 67 (1) ◽  
pp. 138-143 ◽  
Author(s):  
Allen M. Chen ◽  
Joaquin Garcia ◽  
M. Kara Bucci ◽  
Jeanne M. Quivey ◽  
David W. Eisele
Keyword(s):  
Radiation Therapy ◽  
Parotid Gland ◽  
Pleomorphic Adenoma ◽  
Carcinoma Ex Pleomorphic Adenoma ◽  
Postoperative Radiation ◽  
Postoperative Radiation Therapy

scholarly journals Postoperative Radiation Therapy for Parotid Mucoepidermoid Carcinoma

2014 ◽  
Vol 2014 ◽  
pp. 1-4
Author(s):  
Meghan P. Olsen ◽  
Allen O. Mitchell ◽  
Edward F. Miles
Keyword(s):  
Radiation Therapy ◽  
Parotid Gland ◽  
Mucoepidermoid Carcinoma ◽  
Controlled Trials ◽  
Adjuvant Radiation ◽  
Low Grade ◽  
Postoperative Radiation ◽  
Postoperative Radiation Therapy ◽  
Randomized Controlled

Salivary gland cancers are rare and represent approximately 5% of all head and neck cancers and only 0.3% of all malignancies. The majority (75%) of salivary gland tumors occur in the parotid gland, and while benign lesions are more common, mucoepidermoid carcinoma (MEC) makes up 40–50% of malignant parotid gland tumors. No randomized controlled trials exist regarding the role of adjuvant radiation for patients who undergo surgical resection of low-grade MECs. Herein, we report two cases of successful postoperative radiation therapy in low-grade, pT2N0 MEC of the parotid gland. The role of adjuvant radiation therapy for patients with MEC of the parotid gland is based on data from institution reviews and lacks data from randomized controlled trials. Per our review of the literature, the pathological findings of positive surgical margins and/or perineural invasion in two patients with low-grade MEC of the parotid gland warranted adjuvant radiation for improved local control after partial parotidectomy. Both patients tolerated postoperative radiation therapy with only mild side effects and, at last follow-up, five years after completion of therapy, had no clinical or radiographic evidence of either local recurrence or distant metastasis.

Indications and Parameters Around Postoperative Radiation Therapy for Lung Cancer

2022 ◽  
Author(s):  
Antonin Levy ◽  
Olaf Mercier ◽  
Cécile Le Péchoux
Keyword(s):  
Lung Cancer ◽  
Radiation Therapy ◽  
High Risk ◽  
Randomized Trials ◽  
Meta Analysis ◽  
Small Cell ◽  
Postoperative Radiation ◽  
Small Cell Lung ◽  
Postoperative Radiation Therapy

Patients with locally advanced resected non–small-cell lung cancer present a high risk of relapse. Although adjuvant platinum–based chemotherapy has become the standard of care, the role of postoperative radiation therapy (PORT) has been controversial for years. In patients with incomplete resection, PORT should be proposed, on the basis of a strong consensus, despite the absence of randomized evidence. In patients with completely resected (R0) non–small-cell lung cancer, a meta-analysis showed poorer outcomes after PORT in the absence of mediastinal involvement (pN0 and pN1). In patients with pN2, the role of PORT was less clear and required further research. The meta-analysis included trials using older radiation techniques and poorer quality of surgery according to today's standards, and selection of patients was not positron emission tomography–based. Newer retrospective and nonrandomized studies and subgroup analyses of randomized trials evaluating adjuvant chemotherapy suggested a survival benefit of PORT in patients with pN2 R0. Two recent randomized trials (Lung ART and PORT-C) evaluating conformal PORT versus no PORT retrieved no disease-free survival advantage for stage IIIA-N2 patients, even if mediastinal relapse was significantly decreased with PORT. PORT had no effect on survival, possibly given the high rate of distant relapse and risk of additional cardiopulmonary toxicity. Ongoing and future analyses are planned in Lung ART to identify patients for whom PORT could be recommended. Incorporation of newer systemic treatments (immune checkpoint inhibitors or targeted therapy in oncogene-addicted patients) is underway in the neoadjuvant and/or adjuvant setting. Better identification of patients at a high risk of disease recurrence, with analysis of circulating tumor DNA, on the basis of the detection of postsurgical minimal (or molecular) residual disease is warranted in future studies.

Role of postoperative radiation therapy (PORT) in pT1-T2 N0 deep tongue cancers

2015 ◽  
Vol 120 (6) ◽  
pp. e227-e231 ◽  
Author(s):  
Sandhya Gokavarapu ◽  
Nagendra Parvataneni ◽  
L.M. Chandrasekhara Rao S ◽  
Rammohan Reddy ◽  
K.V.V.N. Raju ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Postoperative Radiation ◽  
Postoperative Radiation Therapy
Sign in / Sign up

Export Citation Format

Share Document